BiSpecific mAbS Global Market Opportunities and Strategies to 2032

This report describes and explains the bi-specific mAbs market and covers 2017-2022, termed the historic period, and 2022-2027 termed the forecast period, along with further forecasts for the period 2027-2032. The report evaluates the market across each region and for the major economies within each region.

The global bi-specific mAbs market reached a value of nearly $4,462.4 million in 2022, having grown at a compound annual growth rate (CAGR) of 69.9% since 2017. The market is expected to grow from $4,462.4 million in 2022 to $11,811.0 million in 2027 at a rate of 21.5%. The market is then expected to grow at a CAGR of 13.5% from 2027 and reach $22,255.9 million in 2032.

Growth in the historic period resulted from increased healthcare expenditure, increased funding and government initiatives.

Going forward, an increasing prevalence of cancer, an increasing aging population and an increase in prevalence of chronic diseases will drive market growth. Factors that could hinder the growth of the bi-specific mAbs market in the future include the Russia-Ukraine war and the availability of various alternative treatment methods for cancer.

The bi-specific mAbs market is segmented by type into blinatumomab, emicizumab, amivantamab faricimab and teclistamab. The emicizumab market were the largest segment of the bi-specific mAbs market segmented by type accounting for 86.6% of the total in 2022. Going forward, the amivantamab market is expected to be the fastest growing segment in the bi-specific mAbs market segmented by type, at a CAGR of 44.8% during 2022-2027.

The bi-specific mAbs market is segmented by indication into cancer, hemophilia A and ophthalmic. The hemophilia A market was the largest segment of the bi-specific mAbs market segmented by indication accounting for 86.6% of the total in 2022. Going forward, the ophthalmic market is expected to be the fastest growing segment in the bi-specific mAbs market segmented by indication, at a CAGR of 46.5% during 2022-2027.

The bi-specific mAbs market is segmented by end use into hospitals, research institutes, and other end-users. The hospitals market was the largest segment of the bi-specific mAbs market segmented by end users accounting for 65.5% of the total in 2022. Going forward, the hospitals market is expected to be the fastest growing segment in the bi-specific mAbs market segmented by end users, at a CAGR of 21.9% during 2022-2027.

North America was the largest region in the bi-specific mAbs market, accounting for 62.6% of the total in 2022. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the bi-specific mAbs market will be Western Europe and Asia Pacific where growth will be at CAGRs of 17.2% and 11.5% respectively. These will be followed by the Middle East and South America where the markets are expected to grow at CAGRs of 4.2% and 2.0% respectively.

The global bi-specific mAbs market is highly concentrated, with a small number of large players constituting the majority of the market. The three competitors in the market made up to 100% of the market in 2021. Technological innovations in the recent past helped companies to strengthen their market presence. F. Hoffmann-La Roche AG was the largest competitor with 85.74% share of the market, Amgen Inc with 13.45%, and Johnson & Johnson with 0.81%.

The top opportunities in the bi-specific mAbs market segmented by type will arise in the emicizumab segment, which will gain $5,868.3 million of global annual sales by 2027. The top opportunities in segment by indication will arise in the hemophilia A segment, which will gain $5,868.3 million of global annual sales by 2027. The top opportunities in segment by end use will arise in the hospitals segment, which will gain $4,938.8 million of global annual sales by 2027. The bi-specific mAbs market size will gain the most in the USA at $3,483.4 million.

Market-trend-based strategies for the bi-specific mAbs market include focus on technological advancements, product innovation, focus on artificial intelligence, investment in targeted and combination therapy and strategic partnerships.

Player-adopted strategies in the bi-specific mAbs market include focus on enhancing business operations through securing regulatory approvals, strengthening operational capabilities through strategic acquisitions and strengthening business operations through securing regulatory approvals.

To take advantage of the opportunities, the publisher recommends the bi-specific mAbs companies to focus on artificial intelligence, focus on product innovation, focus on investment in targeted and combination therapy, focus on technological advancements, expand in emerging markets, continue to focus on developed markets, expanding in countries offering research incentives, focus on strategic partnerships, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, continue to target fast-growing end-users and target the aging population.